Publications by authors named "Yasuharu Miyazawa"
Diagnostics (Basel)
June 2024
Article Synopsis
- A study compared the effects of the SGLT2 inhibitor dapagliflozin alone versus its combination with traditional diuretics on fluid retention and vasopressin levels in patients.
- Patients taking the combined treatment showed a significant decrease in copeptin levels, indicating better fluid balance compared to those on dapagliflozin alone.
- The combination therapy effectively reduced fluid retention without dramatically impacting plasma volume or activating stress hormones like renin and aldosterone.
Front Med (Lausanne)
December 2023
Article Synopsis
- Sodium glucose cotransporter 2 (SGLT2) inhibitors, like dapagliflozin, show promise in reducing both blood glucose levels and fluid retention in patients with chronic kidney disease (CKD).
- In a study of 73 patients on dapagliflozin and 24 controls over 6 months, dapagliflozin significantly decreased the extracellular water-to-total body water ratio, indicating improved fluid status, especially among those with initial fluid retention.
- Despite some initial increase in vasopressin levels after one week with dapagliflozin, overall hormone levels including renin and aldosterone did not differ, while sympathetic nervous system markers dropped, suggesting sustained management of body fluid in CKD patients
Diabetol Metab Syndr
May 2020
Article Synopsis
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors like dapagliflozin not only help lower blood sugar but also have a mild diuretic effect, possibly affecting body fluid levels in patients with diabetic kidney disease (DKD).
- In a study, 36 DKD patients treated with dapagliflozin showed significant reductions in body weight and different body fluid components, with more pronounced effects in those who initially had higher extracellular volume levels.
- The results suggest that the initial extracellular volume status plays a crucial role in predicting how patients will respond to dapagliflozin, which could help in managing fluid balance during treatment.
Int Urol Nephrol
September 2019
Article Synopsis
- Tolvaptan, a medication that blocks vasopressin V2 receptors, helps reduce body fluid retention in patients with chronic kidney disease (CKD) but its effectiveness predictors remain unclear.
- In a study with 12 CKD patients treated with tolvaptan, significant reductions in body weight and total body water were noted, without major changes in kidney function (measured by eGFR).
- Serum albumin levels were found to be a relevant predictor of how well patients respond to tolvaptan, suggesting that it could be especially beneficial for patients with low albumin levels.
Nephrology (Carlton)
September 2019
Article Synopsis
- SGLT2 inhibitors like dapagliflozin (DAPA) are medications that help lower blood sugar levels and have diuretic effects, but their impact on fluid distribution compared to traditional diuretics is not well understood.
- A study of 40 chronic kidney disease patients showed that all treatment groups (DAPA, furosemide, and tolvaptan) experienced significant weight loss and increased urine output over 7 days, with notable changes in extracellular water (ECW) levels.
- DAPA led to a smaller reduction in ECW compared to furosemide, but a larger reduction than tolvaptan, indicating that SGLT2 inhibitors may affect fluid distribution differently than conventional diuretics.
Article Synopsis
- * This study involved 90 ESRD patients on hemodialysis, divided into low- and high-FGF21 groups, and tracked mortality and cardiovascular events over roughly 64 months.
- * Results showed that high FGF21 levels correlated with a significantly higher mortality rate (28.3% vs. 9.1%), but did not affect the rate of cardiovascular events, indicating that FGF21 could be a useful marker for predicting mortality in ESRD patients.
Article Synopsis
- Tolvaptan is an oral medication that helps reduce fluid retention in patients with advanced chronic kidney disease, showing a lower risk of harming kidney function compared to typical diuretics.
- In a study involving six patients, tolvaptan significantly decreased both intracellular and extracellular water while increasing urine output and causing a slight reduction in body weight.
- The treatment did not negatively affect kidney function, indicating that tolvaptan provides a different and potentially safer approach to managing fluid retention in these patients.
